Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039910 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00039910 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 240 participants.
The verdict
NCT00039910, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.
Interventions
- DRUG (PN-152,243)/ PN-196,444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2000-07 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039910
The ClinicalTrials.gov registry entry for NCT00039910 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (PN-152,243)/ PN-196,444 is the first listed.
NCT00039910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039910 about?
NCT00039910 is a clinical study titled "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia". Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the preve...
What is the current status of trial NCT00039910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2000-07. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00039910?
The interventions under investigation include: (PN-152,243)/ PN-196,444 (DRUG).
Who is sponsoring clinical trial NCT00039910?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.